Is that pharma influencer human or AI?

Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.

By Meagan Parrish • Nov. 14, 2025

FDA unveils new regulatory roadmap for bespoke drug therapies

The “plausible mechanism” pathway, outlined by Dr. Martin Makary and Dr. Vinay Prasad, is designed to help accelerate treatments custom-made for individuals with rare and serious diseases.

By Ben Fidler • Nov. 13, 2025

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

RNAi looked doomed to fail — until Alnylam’s science chief found a way

Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

By Michael Gibney • Nov. 13, 2025

Drugs are winning approval even when trials fail — but should they?

About 10% of FDA-approved drugs in recent years have won clearance despite a trial failure, raising safety and ethical concerns.

By Kelly Bilodeau • Nov. 12, 2025

After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing

Harout Semerjian, whose pedigree includes launching the Novartis cancer blockbuster Gleevec, is aiming to boost awareness about Geron’s Rytelo to give it momentum.

By Alexandra Pecci • Nov. 12, 2025

Alzheimer’s drug uptake hits its stride after a sluggish start

Sales of Eli Lilly’s Kisunla, and Eisai and Biogen’s Leqembi are on the rise as doctors grow more confident and new dosing options ease treatment hurdles.

By Kelly Bilodeau • Nov. 10, 2025

Pharma’s clinical trial diversity push faces a new threat

Skyrocketing healthcare costs could deliver another blow to the industry’s ongoing quest to boost representation in R&D.

By Meagan Parrish • Nov. 7, 2025

Why Pfizer and Novo are duking it out over weight loss startup Metsera

A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.

By Michael Gibney • Nov. 6, 2025

Chinese drugmaker becomes top trial sponsor — and other clinical trends

The industry’s top indication areas for R&D and other shifts in the clinical trial landscape last year.

By Kelly Bilodeau • Nov. 5, 2025

Biogen’s yearslong lupus R&D journey could soon pay off

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.

By Michael Gibney • Nov. 4, 2025

Roche taps an AI specialist to craft new brain drugs

For $55 million, Roche gains access to Manifold Bio’s drug discovery technology, which will be used to develop new “shuttles” that can get medicines across the blood-brain barrier.

By Jacob Bell • Nov. 4, 2025

Tariffs, pricing, backroom deals — how pharma can navigate wildly shifting policies

Gaming out new regulations and various potential outcomes will help keep companies on more solid footing.

By Kelly Bilodeau • Nov. 3, 2025

Corporate venture firms stepped in for drug startups during biotech funding pullback

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.

By Gwendolyn Wu • Oct. 31, 2025

How Trump’s do-or-die agenda is impacting Big Pharma’s CEO chatter

Among tariffs, pricing policies and ongoing negotiations, pharma leaders can’t help but address their dealings with the Trump administration in third-quarter earnings reports.

By Michael Gibney • Oct. 30, 2025

What comes next for Novo Nordisk?

After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is on Novo to pull off a major about-face.

By Kelly Bilodeau • Oct. 29, 2025

Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience

A premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at revolutionary technology that fits into their own expertise.

By Michael Gibney • Oct. 28, 2025

Merck’s oncology prospects could portend a post-Keytruda future

Can the pharma giant offset potential losses from its megablockbuster with a strong suite of contenders?

By Kelly Bilodeau • Oct. 27, 2025

Takeda stakes more than $11B on cancer drugs from China

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.

By Ben Fidler • Oct. 24, 2025

Massachusetts biotech hub is limping amid layoffs and low investment

The state’s difficulties in the last year are indicative of wider industry problems during a time of market trepidation, as optimism gives way to resilience.

By Michael Gibney • Oct. 23, 2025

AI giants Nvidia, Microsoft and Google are making critical moves in pharma R&D

With market caps in the trillions, these tech behemoths are establishing a growing presence in drug development. Here’s what they’re up to.

By Alexandra Pecci • Oct. 22, 2025

AstraZeneca, Daiichi’s Datroway excels in hard-to-treat breast cancer

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer patients for whom immunotherapy is not an option.

By Delilah Alvarado • Oct. 21, 2025

In the Salesforce vs. Veeva saga, the clock is ticking for drugmakers

The CRM platform split will be official in 2030, but that still doesn’t leave much time for pharmas and biotechs that have yet to choose which way to go.

By Michael Gibney • Oct. 21, 2025

Why a treatment older than the FDA is getting new regulatory scrutiny

MAHA-aligned patients and providers are pushing back to ensure access to an animal-derived thyroid hormone treatment.

By Kelly Bilodeau • Oct. 20, 2025

Pregnant women, long excluded from drug trials, are back in the spotlight

The White House has raised concerns around women’s health, but R&D on pregnant and breastfeeding women is still lacking.

By Meagan Parrish • Oct. 17, 2025

J&J’s orthopedics selloff keeps all eyes on a thriving pharma portfolio

As another J&J department bites the dust, leadership is focused on what’s working in the pharma business, and there’s plenty to see.

By Michael Gibney • Oct. 16, 2025